Hematin therapy in porphyric attacks

C. A. Pierach; I. Bossenmaier; R. Cardinal; M. Weimer; C. J. Watson

doi:10.1007/BF01491103

Hematin therapy in porphyric attacks

C. A. Pierach
, I. Bossenmaier
, R. Cardinal
, M. Weimer
, C. J. Watson

Medicine - Administration

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.

Original language	English (US)
Pages (from-to)	829-832
Number of pages	4
Journal	Klinische Wochenschrift
Volume	58
Issue number	16
DOIs	https://doi.org/10.1007/BF01491103
State	Published - Aug 1980

Keywords

Hematin
Porphyria
Porphyrin precursors

Publisher link

10.1007/BF01491103

Find It

Find It at U of M Libraries

Cite this

@article{2bb24cf7c7d44be8948196603a967e78,

title = "Hematin therapy in porphyric attacks",

abstract = "We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90\% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.",

keywords = "Hematin, Porphyria, Porphyrin precursors",

author = "Pierach, \{C. A.\} and I. Bossenmaier and R. Cardinal and M. Weimer and Watson, \{C. J.\}",

year = "1980",

month = aug,

doi = "10.1007/BF01491103",

language = "English (US)",

volume = "58",

pages = "829--832",

journal = "Klinische Wochenschrift",

issn = "0023-2173",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "16",

}

TY - JOUR

T1 - Hematin therapy in porphyric attacks

AU - Pierach, C. A.

AU - Bossenmaier, I.

AU - Cardinal, R.

AU - Weimer, M.

AU - Watson, C. J.

PY - 1980/8

Y1 - 1980/8

N2 - We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.

AB - We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.

KW - Hematin

KW - Porphyria

KW - Porphyrin precursors

UR - https://www.scopus.com/pages/publications/0018855579

UR - https://www.scopus.com/pages/publications/0018855579#tab=citedBy

U2 - 10.1007/BF01491103

DO - 10.1007/BF01491103

M3 - Article

C2 - 7453089

AN - SCOPUS:0018855579

SN - 0023-2173

VL - 58

SP - 829

EP - 832

JO - Klinische Wochenschrift

JF - Klinische Wochenschrift

IS - 16

ER -

Hematin therapy in porphyric attacks

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this